Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis

科罗拉多大学的一大批研究人员正致力于表征这种分子 风湿性和自身免疫起始阶段和临床前阶段的起源和原因机制 疾病。这些努力的最重要成果之一是在人口中进行了示范- 未来疾病的风险，即粘膜部位的生物失调和慢性炎症可以促进最初的局部 发生疾病特有的对自身抗原的耐受性丧失。最终，这个过程会导致系统性的 自身免疫与类风湿性关节炎(RA)和脊柱关节炎等疾病的发展 (SPA)。以这一概念为基础，拥有独特的高危人群和广泛的方案基础设施， P30风湿病研究资源中心(RDRRC)，题为《黏膜免疫生物学中心 并提出了“风湿病的发病机制”。该中心包括一个管理核心、一个 人口和数据科学核心，以及粘膜免疫生物学核心。这个中心是专门设计的 促进对人类疾病发病机制的研究，包括广泛的粘膜和全身疾病 免疫学技术，以及开发新的方法来研究这些综合的机制 在疾病的临床前阶段和临床活动期招募个体队列。这个 中心包括43名内部和外部成员，他们每年的相关直接成本总计为7700万美元 拨款。除了提供对存储的生物标本和来自持续种群的数据的访问之外 研究，中心将为以下所有关键方面提供咨询和会员折扣机制 队列发展、流行病学评估、数据管理和数据分析。此外，该中心 将为成员提供专注于微生物组和微生物：细胞分析的技术 相互作用，以及提供信息的粘膜和外周免疫生物标志物。该中心将建立在 院长最近投资了8000万美元，为本中心将与之互动的其他四个相关项目提供资金。 医学和免疫学教授迈克尔·霍勒斯博士将担任中心主任，克里斯蒂博士将担任 医学副教授库恩将担任副主任。两者都将与咨询公司互动 和执行委员会，在后者将加入核心董事和联席董事与域 专业知识。作为该中心使命的一个关键组成部分，试点和可行性赠款计划将 在大量的制度支持下发展起来。其他丰富计划活动将包括一个研讨会 系列、技术评估系列和年度研讨会。重点将放在职业生涯的早期。 通过增强的核心访问以及赠款审查和学者计划发展研究人员。 社交媒体、基于网络的外联和通讯将提供全面的交流。最后，一个 患者影响计划将用于评估和加强新生物标记物和 与治疗相关的RDRRC发现了直接的患者护理，目标是改善结果。

A substantial cadre of investigators at the University of Colorado are focused on characterizing the molecular origins and causal mechanisms that drive the initiation and preclinical phases of rheumatic and autoimmune diseases. One of the most important outcomes of those efforts has been the demonstration in populations at- risk for future disease that dysbiosis and chronic inflammation at mucosal sites can promote the initial local development of disease-specific loss of tolerance to autoantigens. Ultimately, this process leads to systemic autoimmunity and the development of diseases including rheumatoid arthritis (RA) and spondyloarthroarthritis (SpA). Building on that concept with unique at-risk populations and an extensive programmatic infrastructure, a P30 Rheumatic Disease Research Resource Center (RDRRC) entitled “Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis” is proposed. Included in the Center are an Administrative Core, a Population and Data Sciences Core, and a Mucosal Immunobiology Core. This Center is specifically designed to facilitate studies of human disease pathogenesis that incorporate the broad range of mucosal and systemic immunologic techniques, as well as develop new approaches, to study these integrated mechanisms in already recruited cohorts of individuals throughout the preclinical and then clinically active phases of disease. The Center includes 43 internal and external members who have in aggregate $77M in related annual direct cost grant funding. In addition to providing access to stored biospecimens and data from ongoing population studies, the Center will provide consultative and member discount mechanisms for all of the critical aspects of cohort development, epidemiologic assessment, data management and data analyses. In addition, the Center will provide members access to technologies that focus on analyses of the microbiome and microbial:cell interactions, as well as informative mucosal and peripheral immune biomarkers. The Center will build on a recent $80M investment from the Dean to fund four other relevant programs with which this Center will interact. Dr. Michael Holers, Professor of Medicine and Immunology, will serve as the Center Director, and Dr. Kristi Kuhn, Associate Professor of Medicine, will serve as the Associate Director. Both will interact with Advisory and Executive Committees, and in the latter will be joined by Core Directors and Co-Directors with domain expertise. As a key component of the mission of the Center, a Pilot & Feasibility Grants Program will be developed with substantial institutional support. Additional Enrichment Program activities will include a seminar series, technology assessment series, and an annual symposium. A major focus will be on early career investigator development through enhanced Core access as well as Grants Review and a Scholars Programs. Social media, web-based outreach and newsletters will provide comprehensive communication. Finally, a Patient Impact Program will be utilized for the assessment and enhanced translation of novel biomarkers and therapeutically relevant RDRRC discoveries into direct patient care with the goal to improve outcomes.